Skip to main content
. 2019 May 9;20(9):2296. doi: 10.3390/ijms20092296

Figure 5.

Figure 5

Protein kinase inhibitors can selectively inhibit the activity of their targeted altered kinase leading to PD-L1 downregulation and restoration of both apoptosis and MHC-I expression. Combination therapies with PD-1/PD-L1 blocking therapies will result in enhanced T-cell response against tumor cells. RK (receptor kinase), RKI (receptor Kinase Inhibitor), KI (kinase Inhibitor), Pan-KI (pan-kinase inhibitor), TCR (T-cell receptor). PTEN-M: PTEN modulator.